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Dear Editor,
The myeloproliferative disorders (MPDs) constitute a subcategory of chronic myeloid disorders and include chronic myeloid leukemia (CML), essential thrombocytemia (ET), polycythemia vera (PV) and myelofibrosis (MF). In 1960, the discovery of the Philadelphia chromosome (Ph) became a cornerstone in CML treatment and led to the development of moleculary targeted therapy. Recently, an acquired mutation in the Janus kinase 2 (JAK2) gene has been discovered in nearly all patents with PV and approximately half of the patients with primary MF and ET. Subsequently, the mutation has been demonstrated in atypical MPDs (chronic neutrophilic leukemia, unclassified), de novo myelodysplastic syndrome or acute myeloid leukemia. 1 It has been hoped that targeted inhibition of JAK2V617F should achieve similar disease control as thyrosine kinases has produced in CML.
A gain-of-function mutation at codon 617 (V617F) of the JAK2 gene causes constitutive activation of the JAK-STAT pathway which in turn leads to uncontrolled hematopoietic cell proliferation.
2 In mice, JAK2V617F induces a PV-like disease with erythrocytosis, low serum erythropoietin (Epo) level, splenomegaly, extramedullary hematopoiesis, megakaryocytic hyperplasia, and anemia.
2, 3 Tefferi suggested that JAK2V617F mutation probably leads to a PV-weighted MPD phenotype. 1 Jelinek et al. reported no mutated cases for JAK21849G>T in 99 CML patients, including 55 imatinib-resistant subjects. 4 Similarly, Bock et al. did not detect JAK2 mutation in 5 Ph + CML patients in a previous report. 5 In contrast with these reports, more recently, several cases with the coexistence of BCR-ABL fusion gene and JAK2V617F mutation in blood and bone marrow samples were reported. [6] [7] [8] [9] [10] [11] [12] [13] We report here a new case with concomitant BCR-ABL rearrangement and JAK2V617F mutation, and compare our findings with those of similar reports.
A 58-year-old female patient presented with ruddy face, dizziness, flushing and pruritis. Physical examination was normal with no palpable spleen enlargement. The hematological parameters were as follows: white blood cells, 20.3x10 9 /L with a differential count of 83% neutrophils; hemoglobin, 16.9g/dL; hematocrite, %56,4; platelets 387x10 3 / µl. Peripheral smear revealed thrombocytosis and left shift of the myeloid series. Iron deficiency and inflammation were ruled out. The leukocyte alkaline phosphatase (LAP) score was below 10%. Arterial blood gas analysis revealed a normal oxygen saturation. Serum Epo levels were found lower than Histopathologic examination of bone marrow biopsy revealed 95% cellularity, markedly increased myeloid series, decreased blast ratio (<0.05), increased myeloid/erythroid ratio (5/1) and increased dismature megacaryocytes. Immünohistochemical staining with prussian blue revealed decreased iron deposits and stage 0 CML was reported in according to reticulin fibrosis score. Abdominal ultrasound examination has no pathologic findings related with spleen, liver and the other organs. Cytogenetic analysis revealed no cytogenetic abnormality. The examination of peripheral blood samples by using PCR revealed that BCR-ABL (P210) was 0.01. Translocation (t 9;22) was found 8% positive in FISH study by using BCR-ABL translocation probe. As a part of diagnostic evaluation of MPDs, JAK2V617F mutation analysis was performed and was found to be positive in according to Rotor gen real time PCR analysis in peripheral blood. Therefore, the coexistence of JAK2 mutation and Philadelphia chromosome (Ph + ) was observed in a single patient. These results revealed the diagnosis of a myeloproliferative disease (CML/PV) and imatinib therapy was started at 400 mg/day.
There is a debate as to whether MPD and CML arise separately from each other, representing independent development from a normal stem cell, or whether the Ph chromosome arises in a stem cell of a MPD clone.
11
The unexpected hematological responses (including thrombocytosis), 7 or erythrocytosis, 8, 9 evolving myelofibrosis, 10, 11 and/or persisting spleen enlargement, 7, 12 under imatinib mesylate treatment led some physicians to detect for JAK2 mutation in either peripheral blood or bone marrow. Probably, imatinib therapy suppresses the BCR-ABL clone, enabling the proliferation of JAK2V617F mutated cells. It is likely that the dominance of JAK2 positive clone obtain an escape effect which may explain the mechanism of bone marrow fibrosis and also hematological changes. Campiotti et al. have prospectively detected JAK2 mutation positivity in one patient among 13 new cases of Ph + positive CML. 13 In contrast with other reports; 7-12 after the partial cytogenetic response to imatinib treatment, JAK2 mutation was disappeared. Therefore, they have firstly hypothesized that imatinib treatment have caused the regression of CML clone, as well as JAK2 mutated cells, and that JAK2 mutation can be acquired by Ph + cells , 13 But in most cases, as described previously, imatinib mesylate therapy did not effect the coexisting and/or acquired JAK2 clone, [7] [8] [9] [10] [11] [12] Moreover, owing to a proliferative advantage, JAK2 mutated hematopoiesis could overwhelm the BCR-ABL translocated hematopoiesis. To our knowledge, it seems more likely that there are two independent growing aberrant stem cell clones.
On the other hand, some patients with preexisting JAK2V617F positive MPD were found to have Philadelphia translocation in the literature. Eventhough the JAK2V617F mutation has been excluded in a large cohort of BCR-ABL patients, 4 the present report gives evidence that the coexistence of these two disease-spesific mutations is possible. Physicians have to keep in mind that unexpected hematological responses, evolving myelofibrosis, and/or persisting spleen enlargement during effective treatment of Ph + CML may be caused by an underlying JAK2 positive hematopoietic clone.
